SCHEMBL19631585

SCHEMBL19631585

CC1(C)CC(C#N)(N2CCN(Cc3ccccc3)CC2)CC(C)(C)O1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.47
OPRM1 P35372 1/20 0.47
MC4R P32245 1/20 0.45
LMNA P02545 2/20 0.44
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ABCB1 P08183 1/20 0.42
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HIF1A Q16665 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KCNA3 P22001 1/20 0.41
DRD4 P21917 1/20 0.41
ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18458522 0.85 ALDH1A1 (0.56) SIGMAR1OPRM1MC4RLMNAPOLB
SCHEMBL22441511 0.82 OPRM1 (0.59) SIGMAR1OPRM1MC4RLMNAPOLB
SCHEMBL19631845 0.81 ALDH1A1 (0.52) SIGMAR1OPRM1MC4RLMNAPOLB
SCHEMBL18458521 0.81 SIGMAR1 (0.53) SIGMAR1OPRM1MC4RLMNAPOLB
SCHEMBL18458358 0.79 OPRM1 (0.56) SIGMAR1OPRM1MC4RLMNAPOLB
SCHEMBL14279621 0.78 MC4R (0.59) SIGMAR1OPRM1MC4RLMNAPOLB
SCHEMBL18458363 0.78 OPRM1 (0.52) SIGMAR1OPRM1MC4RLMNAPOLB
SCHEMBL3523156 0.78 OPRM1 (0.52) SIGMAR1OPRM1MC4RLMNAPOLB
SCHEMBL5199646 0.78 OPRM1 (0.55) SIGMAR1OPRM1MC4RLMNAPOLB
SCHEMBL14836350 0.78 OPRM1 (0.55) SIGMAR1OPRM1MC4RLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10807970-B2 Tetrahydropyran and thiopyran derivatives having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. (ES) 2020-10-20 US disclosed
EP-3458450-B1 TETRAHYDROPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS SA (ES) 2020-07-01 EP disclosed
US-20190241544-A1 TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-08-08 US disclosed
WO-2017198339-A1 TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2017-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241544-A1 TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRD1, SIGMAR1, OPRK1 SIGMAR1 2/4885OPRM1 4/4885MC4R 148/4885
US-10807970-B2 Tetrahydropyran and thiopyran derivatives having multimodal activity against pain OPRD1, SIGMAR1, OPRK1 SIGMAR1 2/4885OPRM1 4/4885MC4R 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.